Kornimate/medical-research-clean huggingface dataset:
strain imaging in breast cancer patients receiving trastuzumab

Conditions: Her 2 Positive Breast Cancer

Summary: the purpose of this research study is to evaluate the effects of the chemotherapeutic drug, trastuzumab (herceptin) on the heart. trastuzumab (herceptin) is used to treat specific types of breast cancer and is known to cause weakening of the heart. unfortunately, little is know as to why this this happens. the investigators want to identify any factors that may lead to the early detection, treatment and prevention of the cardiotoxicity (heart problem) associated with this drug.

as a subject participating in this study the following information will be collected: complete past medical history including age, height, and weight will be done with each echocardiogram; blood pressure at clinic visits during treatment with trastuzumab, type of cancer will be noted, type of chemotherapy, doses of chemotherapy, type and dose of chemotherapy in the past, type and dose of radiation therapy received, names and doses of cardiac medications, results of cardiac tests, results of lab tests, family history of heart disease, and social history which will include risk factors for developing heart disease including tobacco and alcohol use. this information will be entered into a database for the investigators to try and detect any factors that may lead to the cardiotoxicity (heart problem) that may be caused by trastuzumab (herceptin). any transthoracic echocardiogram (heart ultrasound) ordered will be further evaluated for special parameters that may help to detect weakening of the heart earlier than a normal ultrasound. an echocardiogram (heart ultrasound) is when a probe is placed on the chest and pictures are taken using sound waves and a special camera.

Eligibility criteria:
inclusion criteria: * age greater than 18 years * her 2 positive breast cancer. * patients who are currently receiving trastuzumab (herceptin). * patients who received trastuzumab (herceptin) after the formation of the ufhealth medical plaza pharmacy database was initiated. exclusion criteria: * age less than 18 years * patients who have not received trastuzumab (herceptin). * patients who received trastuzumab prior to the formation of the ufhealth medical plaza pharmacy database.

Keywords: her 2 positive breast cancer trastuzumab herceptin heart failure echocardiography
open label study to assess efficacy and safety of the fully human anti-tnf-alpha monoclonal antibody adalimumab

Conditions: Rheumatoid Arthritis

Summary: the study was to explore the efficacy of adalimumab in subjects previously treated with infliximab and failed infliximab treatment due to lack of efficacy or intolerance. to explore the safety of adalimumab in subjects previously treated with infliximab.


Eligibility criteria:
inclusion criteria: * males and females \>= 18 years of age * acr criteria for ra diagnosis for at least 6 months * active ra defined as a das 28 \>3.2 at study entry * unsatisfactory response, loss of response or intolerance to prior infliximab treatment * a negative pregnancy test for females of childbearing potential exclusion criteria: * patient who had previous treatment with cyclophosphamide and chlorambucil * treatment within the last 8 weeks with infliximab * prior treatment with more than one dmard or dmard combination following infliximab treatment * prior treatment with biologics (investigational or commercial) ra therapies other than infliximab * history of cancer, other than successfully treated squamous cell or basal cell carcinoma or lymphoproliferative disease * prior treatment with total lymphoid irradiation
perspectives of receiving open versus minimally invasive surgery

Conditions: Lung Cancer; Esophageal Cancer

Summary: this study will examine the perspectives of patients' undergoing surgery for lung or esophageal cancer. it will examine both pre-op and post-op patient perspectives and opinions regarding pain and surgical complications. this study will also assess a general health related quality of life pre-op and post-op. additionally, it will examine the importance of receiving care close to home and their support system. hypotheses: 1. the data will allow investigators to better understand the willingness of patients to participate in prospective, randomized studies comparing minimally invasive and open thoracic surgery. patients will not be willing to undergo randomization to an open versus minimally invasive surgical procedure. 2. the pain associated with minimally invasive surgery (mis) will be perceived and documented as lesser than open surgery. 3. patients may be willing to accept a higher risk of complications or more post-operative pain if they were given the option to be cared for closer to their home.


Eligibility criteria:
inclusion criteria: * patients who are surgical candidates for lung or esophageal cancer (entered at pre-op time point) exclusion criteria: * below 18 years of age.

Keywords: minimally invasive surgery patient perspectives lung cancer esophageal cancer pain
the outcomes of subject after total knee arthroplasty

Conditions: Satisfaction, Patient

Summary: total knee arthroplasty (tka) is a standard of intervention for severe knee osteoarthritis, also been proven with benefits in improving pain, mobility, and quality of life. however, the outcomes after tka is controversial.

total knee arthroplasty (tka) clinical pathway provides preoperative education, postoperative rehabilitation, and routine outpatient follow-up. the overall functional performance of the patient was assessed. the aim of this study was to analyze (1) clinical pain relief, anxiety reduction and functional recovery after tka; (2) factors affecting individual functional recovery, such as age, gender, bmi, etc. the results can be used as a reference for improving the quality in tka patients.

Eligibility criteria:
inclusion criteria: * unilateral knee tka exclusion criteria: * bilateral knee tka

Keywords: total knee arthroplasty (tka) western ontario and mcmaster universities arthritis index
culturally tailored hpv psychoeducational multimedia intervention

Conditions: Health Knowledge, Attitudes, Practice; Vaccine-Preventable Diseases; Intention; Adherence, Patient

Summary: community members ages 18 - 45 years old from the el paso, texas, u.s.-mexico border region will be recruited to compare psychoeducational multimedia interventions focused on the human papillomavirus (hpv). our hypothesis is that adults who view culturally tailored multimedia stories encouraging hpv vaccination will report higher vaccine uptake rates.

a sample of vaccine-naive (unvaccinated or under-vaccinated) adult community members ages 18 - 45 years old from the el paso, texas, u.s.-mexico border region, will be recruited to participate in a human papillomavirus (hpv) multi-media intervention. hypothesis: vaccine-eligible adults who view culturally tailored multimedia stories encouraging hpv vaccination will report significantly stronger vaccine intentions and, subsequently, significantly higher vaccine uptake rates when compared to vaccine-eligible adults exposed to a standard hpv vaccination fact sheet and generic hpv vaccine videos.

Eligibility criteria:
inclusion criteria: * adults between the ages 18 and 45 years old * adults who have not completed the hpv vaccine series (unvaccinated or under-vaccinated) * adults currently living or working in el paso county, texas exclusion criteria: * adults who participated in phases i or ii of the larger research project \[cross-sectional phases\] * adults younger than 18 years of age * adults older than 45 years of age * adults that do not reside, plan to live or work in el paso county, texas, within the next 12 months after the start of the intervention * adults who are unable to participate in the full study intervention and follow-up time-points * adults who cannot complete study participation and activities in either the english or spanish languages.

Keywords: human papillomavirus vaccination human papillomavirus cancer screening hpv cancer prevention hpv cancer mitigation sexual and reproductive health u.s.-mexico border health behavioral research community engaged research health disparities health inequities social determinants of health male female adult young adult
fibroid ablation study

Conditions: Leiomyoma; Uterine Fibroids; Menorrhagia

Summary: the primary objective of this study is to establish the effectiveness and confirm the safety of the vizablate system in ablating symptomatic uterine fibroids.


Eligibility criteria:
inclusion criteria: * 28 years of age or older * regular, consistent menstrual cycles * history of excessive bleeding * one menstrual pictogram score ≥ 120 during a one-month screening period * baseline uterine fibroid symptom \& quality of life (ufs-qol) symptom severity subscale (sss) score ≥ 20 * between 1 and 5 target fibroids between 1 cm and 5 cm and/or maximum volume 82.4cc * at least one fibroid must indent the endometrium * subject is not at material risk for pregnancy. * subject is willing to maintain use or non-use of hormonal contraception * subject is willing to have uniform maintenance (use or non-use) of any antifibrinolytic or nonsteroidal anti-inflammatory agents exclusion criteria: * subserosal fibroids with bulk symptoms * presence of type 0 intracavitary fibroids * any target fibroid \> 5 cm in maximum diameter with a volume \> 82.4cc * any fibroid that obstructs access of the vizablate probe * postmenopausal by history * desire for current or future fertility * hemoglobin \< 6 g/dl * pregnancy * evidence of disorders of hemostasis * use of gonadotropin-releasing hormone (gnrh) agonist or implantable or injectable progestin and/or estrogen, selective estrogen receptor modulators (serm) or selective progesterone receptor modulator (sprm) * short-term use of hormonal medication for management of bleeding * evidence for current cervical dysplasia * endometrial hyperplasia * confirmed abdominal / pelvic malignancy within the previous five years * active pelvic infection * clinically significant adenomyosis * previous uterine artery embolization. previous surgical or ablative treatment for fibroids or menorrhagia within previous 12 months * current use of anticoagulant therapy * need for emergency surgery to treat fibroid symptoms * concomitant intrauterine polyps \> 1.0 cm * contraindication to mri * renal insufficiency * uncontrolled hypertension lasting 2 years or more * one or more treatable fibroids that are calcified * chronic pelvic pain * presence of an extrauterine pelvic mass * presence of a tubal implant for sterilization * previous pelvic irradiation * endometrial cavity length \< 4.5 cm

Keywords: uterine fibroid rf ablation intrauterine ultrasound vizablate
effect of phosphorus supplementation on body weight

Conditions: Body Weight

Summary: phosphorus is a mineral that is naturally present in our foods and is required by our bodies for normal function. it has been found that phosphorus supplementation taken before meals has the potential to reduce meal size. however its long term effect has not been measured yet. it is well accepted that changes in body weight require about 3 months. using body weight as the outcome, which is the ultimate outcome of weight loss approaches, would provide robust information on the role of phosphorus.

a double-blind, randomised, placebo-controlled trial of 63 adults aged 18 to 45 years with a body mass index (bmi) of 25 kg/m2 or higher and normal kidney function at the american university of beirut. participants were randomly assigned to the placebo or phosphorus group where daily placebo or phosphorus supplements were ingested with three main meals (breakfast, lunch, and dinner) for a period of 12 weeks. primary outcomes were changes in anthropometric measures, blood metabolites (including lipid profile, glucose, and insulin), and subjective appetite scores.

Eligibility criteria:
inclusion criteria: * bmi\>25 * cr\>1mg/dl for women; cr \>1.2 mg/dl for men * gfr \>60ml/min/1.73m2 exclusion criteria: * bmi\<25 * presence of any significant medical disease, * pregnancy or lactation, * regular administration of drugs that affect body weight, and * weight loss of 3% or more within 3 months of study entry.

Keywords: phosphorus intake
feasibility of meal delivery postpartum

Conditions: Postpartum Weight Retention; Obesity

Summary: this study is being done to assess the feasibility and acceptability of a meal delivery intervention among low-income postpartum women with obesity.

this is a single-group pilot study in which subjects will receive 10 home-delivered meals per week for 8 weeks.

Eligibility criteria:
inclusion criteria: * medicaid eligible and/or have a household income at or below 185 percent of the federal poverty line * 18 years of age or older * initiated prenatal care at a university of alabama at birmingham prenatal clinic * experienced a healthy singleton pregnancy * 5-18 weeks postpartum at enrollment * body mass index \>= 30 at enrollment * residing within the meal company's delivery radius * willing to consent exclusion criteria: * self-reported major health condition (such as renal disease, cancer, or type 1 or type 2 diabetes) * current treatment for severe psychiatric disorder (such as schizophrenia) * self-reported diagnosis of anorexia or bulimia * current use of medication expected to significantly impact body weight * current substance abuse * participation in another dietary and/or weight management intervention postpartum * unable to understand and communicate in english * unwilling or unable to consume study meals

Keywords: postpartum weight management meal delivery
epidemiology of interstitial lung disease

Conditions: Lung Diseases; Lung Diseases, Interstitial

Summary: to establish a population-based registry of interstitial lung disease in bernalillo county, new mexico.

background: although many investigations have been conducted to characterize the pathogenesis of interstitial lung diseases, few examined the epidemiology of these disorders in a general population. the establishment of the registry represented the first step in a sequence of investigations designed to characterize the epidemiology of the interstitial lung diseases. the registry initially served a descriptive purpose; the incidence of the interstitial lung diseases was measured in a defined population. subsequently the registry served as a mechanism for ascertaining cases for a case-control study. finally, the registry provided population-based data for clinical purposes on presentation, physiology, and natural history of the interstitial lung diseases. design narrative: the resources of the new mexico tumor registry were adapted to identify new cases of interstitial lung disease in bernalillo county. other sources of information for identifying new cases included pulmonary physicians, primary care physicians, death certificates, and autopsies. after a case of interstitial lung disease had been identified from the various sources of information, data collection included an interviewer-administered symptoms questionnaire, abstracted medical record data, phlebotomy for measurement of serum precipitins, and evaluation of available chest x-rays and biopsy materials. follow-up was used to determine the natural history of the disease. the study was renewed in 1993 to complete the work conducted from 1988 through 1992. case-ascertainment, data collection, and follow-up of incident cases of ild identified during the period 10/1/88-9/30/92 were completed. the incidence of ilds was described. the clinical characteristics of patients with ilds were described. the prognosis of the most common ilds were described.

Eligibility criteria:
no eligibility criteria
non-interventional study of ocrelizumab in participants with relapsing or primary progressive multiple sclerosis

Conditions: Multiple Sclerosis

Summary: this is a multicentre non-interventional study aimed at evaluating the real-world effectiveness and safety of ocrelizumab treatment in participants with relapsing multiple sclerosis (rms) or primary progressive multiple sclerosis (ppms), who have been prescribed ocrelizumab as per routine practice. this study will use a comprehensive combination of participant reported outcomes and conventional multiple sclerosis (ms) endpoints that measure clinical domains commonly affected by ms (e.g. fatigue, hand function, gait, cognition), and their impact on employment, activities of daily living, quality of life and healthcare resource utilization. the incidence, type, and pattern of serious adverse events (saes), and of adverse events (aes) leading to treatment discontinuation will also be determined.


Eligibility criteria:
inclusion criteria: * must have a definite diagnosis of rms or ppms and in whom a decision to initiate ocrelizumab has been taken as part of routine clinical practice * must be prescribed ocrelizumab in line with the smpc * must have provided signed informed consent * must be able and willing to complete the pros as per clinical practice exclusion criteria: * previously treated with ocrelizumab (including phase ii, phase iii and phase iiib clinical trials, local trials and investigator initiated study (iis) as well as a pre-approval access or compassionate use programmes or local registries that are not compatible with the musicale study design) * not receiving ocrelizumab in line with the smpc
interrogating fatty acid metabolism impairment and clinical correlates in males with klinefelter syndrome

Conditions: Klinefelter Syndrome

Summary: this study will learn more about how the body uses energy. usually, the body uses sugars as energy first and then fats are used when the sugar stores are gone. some people have trouble using fats as energy. this can lead to feeling tired, difficulty exercising, and storing too much fat where it does not belong (like in the muscle). it is believed that some boys and men with klinefelter syndrome may not be able to use fats as energy normally, and that a medication called fenofibrate could help this.


Eligibility criteria:
inclusion criteria: * male * ages 15 to 40 years * total testosterone concentration within the normal range for age and pubertal stage * for the ks group only: genetic testing results confirming ks exclusion criteria: * liver disease (alt or ast \> 3x upper limit of normal) * renal impairment (estimated creatinine clearance \<80 ml/min) * diabetes mellitus (a1c \> 6.4%) * untreated hypogonadism * treatment with a ppar agonist (including fish oil) or statin within the past month * unstable medications with any medication added or removed within the past 2 weeks or plan for medication changes during the study period * inability to tolerate study procedures, including any medical conditions that make exercise unsafe at the discretion of the study physician * for the ks group only: known allergy to fibrates, inability to swallow tablets

Keywords: klinefelters xxy 47, xxy klinefelter's syndrome klinefelter
standard scale for syndrome differentiation of yin deficiency syndrome

Conditions: Yin Deficiency Syndrome

Summary: an version of the standard scale for syndrome differentiation of yin deficiency syndrome is not available yet for chinese medicine. the aim of this study is to develop and validate the standard scale for syndrome differentiation of yin deficiency syndrome. the study is divided into two steps. the first step is to develop the standard scale for syndrome differentiation of yin deficiency syndrome through expert consultation (delphi method). the second step is to apply the scale in the participants and find out the diagnostic cut-off value of the scale by comparing it with the gold standard.


Eligibility criteria:
inclusion criteria: * subject will be recruited from the current outpatients' clinic activity of the affiliated hospitals of beijing university of chinese medicine and nanjing university of chinese medicine. subjects must be able to read and write in chinese. after obtained informed consent we will ask them to participate to this study. * all the subjects need to fill in the scale of yin deficiency syndrome and be diagnosed by a specialist in traditional chinese medicine (tcm) to determine whether they have yin deficiency syndrome. the judgment of tcm experts is the gold standard. exclusion criteria: * participates who not meet eligibility criteria

Keywords: standard scale syndrome differentiation yin deficiency syndrome
gnrh agonist administration in the luteal phase of icsi-et cycles

Conditions: Infertility

Summary: a single dose gnrh agonist administration in the luteal phase of assisted reproduction cycles was reported to increase pregnancy and birth rates. this study was done to evaluate the reproducibility of previous findings.

gnrh agonist administration in the luteal phase was reported to beneficially affect clinical outcome of icsi-et cycles. this randomized controlled trial evaluates the effect of a single dose gnrh agonist administered in the luteal phase on the outcome of icsi - et cycles stimulated with the long gnrh agonist protocol. women undergoing embryo transfer following controlled ovarian hyperstimulation with a long gnrh agonist protocol were included. in addition to routine luteal phase support with progesterone women were randomized to receive a single dose of gnrh agonist or placebo on the sixth day after icsi.ongoing pregnancy rate was the primary outcome measure.

Eligibility criteria:
inclusion criteria: * women undergoing embryo transfer following controlled ovarian hyperstimulation with a long gnrh agonist protocol, oocyte pick-up and icsi. * embryo transfer performed on day 3. exclusion criteria: * participation in another trial that was being conducted in our unit at the same time. * preimplantation genetic screening cycles. * day 5 embryo transfers.

Keywords: gnrh agonist ivf/icsi outcome luteal phase
the use of probiotics in patients with symptomatic oral lichen planus

Conditions: Oral Lichen Planus; Candida Infection

Summary: the aim is to investigate the effect of probiotic bacteria on symptoms and clinical manifestations in patients with oral lichen planus (olp). the hypothesis is that probiotic bacteria can favor an oral environment that reduces the risk of symptomatic candidal and bacterial infection in olp. the negative influence of improper oral hygiene on olp is established and overgrowth of candida is a common problem. nystatin is the only topical antifungal that does not interact with other drugs and to which the majority of the candida species are susceptible. symptomatic treatment with fluocinolone is initiated in patients without candidal infection. probiotic bacteria can affect the microbial homeostasis by reducing the overgrowth of pathogens e.g. candida. different probiotic species have been shown to produce antifungal substances and reduce the growth of candida albicans in vitro. the probiotic strain lactobacillus rhamnosus has been found to reduce the salivary count of yeasts among elderly in a randomized clinical study. the study is planned as a blinded, randomized controlled study with four parallel arms. 120 olp patients with symptoms form the mucous membranes are included in the study and will receive nystatin or fluocinolone treatment depending on positive or negative diagnosis of candidosis. in addition, they will be assigned to either the probiotic (a) or the placebo group (b) by randomization. the groups will be encouraged to take three tablets per day (morning, noon and evening)for eight weeks. the lozenges containseither two strains of the probiotic bacterium l. reuteri (a) or placebo (b). cytosmears, saliva sample, and saline mouth wash will be taken at baseline, after the treatment period and at follow-up visits at 8, 16, 24 weeks and 1 year. salivary counts of the probiotic strains, the clinical manifestations and symptoms associated to olp will be recorded.


Eligibility criteria:
inclusion criteria: * symptomatic oral lichen planus exclusion criteria: * antibiotic treatment within 3 months

Keywords: probiotic candida oral lichen planus